Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39

Benzinga Newsdesk www.benzinga.com Neutral 49.6%

Neg 0% Neu 49.6% Pos 0%

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.